<2>Thienylmercapto-essigsaeure-amid | 14725-29-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: <2>Thienylmercapto-essigsaeure-amid
• 英文别名: <2>Thienylmercapto-acetamid；[2]thienylmercapto-acetic acid amide；[2]Thienylmercapto-essigsaeure-amid；2-(2-Thienylthio)acetamide；2-thiophen-2-ylsulfanylacetamide
• CAS: 14725-29-2
• 化学式: C₆H₇NOS₂
• 分子量: 173.26
• InChiKey: RVVYKKKYUHVFBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  96.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 2-(thiophen-2-ylthio)acetate 在 氨 、 水 作用下， 生成 <2>Thienylmercapto-essigsaeure-amid
  参考文献：
  名称：

  Family Structure: Its Effects on Adolescent Attachment and Identity Formation

  摘要：

  This quantitative study examines the association between family structure, attachment, and identity formation. Results partially support the hypotheses and indicate that unresolved spouse conflict is associated with low levels of attachment in adolescents and attachment to father is linked to identity achieved and the diffused identity status. Lastly, parental coalition was inversely related to the moratorium and diffused identity statuses. These findings support a link between parent/adolescent relationships and the identity formation process. Directions for future research and clinical implications are also discussed.

  DOI：

  10.1080/01926180390201945

文献信息

• Isoxazolone derivatives and production thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0250096A1

  公开（公告）日：1987-12-23

  The present invention related to a compound of the formula : wherein R1 is hydrogen, isonitrile or an organic residue bonded through nitrogen ; R is hydrogen, alkyl ' which may be substituted, alkylthio in which sulfur atom may be oxidized or azido, or forms a double bond together with the adjacent carbon atom; provided that when R1 is an organic residue bonded through nitrogen, R is not hydrogen; R2 is carboxyl or a group derivable therefrom, and a salt thereof, and a method for producing the same. The Compound (I) of the present invention has, among others, an excellent anitimicrobial activity and is useful as an antimicrobial agent, etc.

  本发明涉及一种具有以下结构的化合物：其中R1是氢、异腈或通过氮原子键合的有机残基；R是氢、可以被取代的烷基、硫代烷基（其中硫原子可能被氧化）或偶氮基，或者与相邻碳原子形成双键；但是当R1是通过氮原子键合的有机残基时，R不是氢；R2是羧基或可由其衍生的基团，以及其盐，以及生产该化合物的方法。本发明的化合物（I）具有优异的抗微生物活性，可用作抗微生物剂等。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• Antibiotic isoxazole derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0191989A1

  公开（公告）日：1986-08-27

  The compounds of the formula: wherein R1 is amino or an organic residue bonded through nitrogen; R2 is carboxy or a group derivable therefrom; X is hydrogen, methoxy or formylamino, provided that when R' is acetylamino or amino and X is hydrogen, R2 is not paranitrobenzyloxycarbonyl or benzhydryloxycarbonyl or salts thereof exhibit excellent antimicrobial activity, and are utilized as antimicrobial agents.

  式中的化合物： 其中 R1 是氨基或通过氮键连接的有机残基；R2 是羧基或可由其衍生的基团；X 是氢、甲氧基或甲酰氨基，条件是当 R' 是乙酰氨基或氨基且 X 是氢时，R2 不是对硝基苯氧基羰基或苯甲酰氧基羰基或其盐，这些化合物具有优异的抗菌活性，可用作抗菌剂。
• Antibiotic derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0219923A1

  公开（公告）日：1987-04-29

  The compound represented by the formula: where R' stands for amino or an organic residue bonded through nitrogen; R2 stands for carooxyl ora group derivable therefrom; R3, R4, R5, R6, R7 and R8 independently stand for hydrogen or an organic residue, including the case where R5 or R6 forms a chemical bond or a ring with R7 or R8: X stands for hvdrogen, methoxy or formylamino; or a salt thereof, pro- duceaole by the present method. exnibits excellent antimicrobial activity, and is utilized as antimicrobial agents.

  式所代表的化合物： 其中，R'代表氨基或通过氮键结合的有机残基；R2代表甲氧羰基或可由其衍生的基团；R3、R4、R5、R6、R7 和 R8 分别代表氢或有机残基，包括 R5 或 R6 与 R7 或 R8 形成化学键或环状的情况：X 代表氢、甲氧基或甲酰氨基；或其盐，通过本方法制得。它们具有优异的抗菌活性，可用作抗菌剂。
• Tricyclic penam compounds, their production and their use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0249909A1

  公开（公告）日：1987-12-23

  The compounds, having a 4,10-dioxo-3-oxa-7-thia-1- azatricyclo[6,2,0,02,6]decane-2-carboxylic acid skeleton as the base structure, their esters and their salts, are useful antibacterial agents.

  这些化合物以 4,10-二氧代-3-氧杂-7-硫杂-1-氮杂三环[6,2,0,02,6]癸烷-2-羧酸骨架为基础结构、 它们的酯类和盐类是有用的抗菌剂。